Tools for Practice Outils pour la pratique


#322 A dose a day keeps the UTI away?


CLINICAL QUESTION
QUESTION CLINIQUE
 What is the efficacy of antibiotic prophylaxis for recurrent urinary tract infections (UTI) in non-pregnant women?

BOTTOM LINE
RÉSULTAT FINAL
 Antibiotic prophylaxis decreases the risk of recurrent UTIs from 66% with placebo to 12% with prophylaxis over 6-12 months. More women will experience an adverse event with antibiotics (15% versus 8% with placebo). Long-term bacterial resistance and its individual clinical impact has not been well studied.


CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

 Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session


EVIDENCE
DONNÉES PROBANTES
  • Antibiotic prophylaxis for 6-12 months compared to placebo:
    • Meta-analysis, 10 Randomized Controlled Trials (RCTs), 430 women, 5 different antibiotics, varying regimens.1
      • ≥1 microbiological recurrence, 8 RCTs, 372 women: 12% versus 66% placebo; number needed to treat (NNT)=2.
      • ≥1 clinical UTI (example dysuria), 8 RCTs, 257 women: 7% versus 51% placebo; NNT=3.
      • Adverse events (most commonly skin rash, nausea): 15% versus 8% placebo, number needed to harm=14.
      • No difference in serious adverse events.
      • Limitations: Small studies, many >25 years old.
    • RCT not in above meta-analysis, 302 women, fosfomycin 3g every 10 days versus placebo for 6 months.2
      • ≥1 microbiological recurrence: 7% versus 75% placebo; NNT=2.
    • Antibiotic prophylaxis for 6-12 months compared to non-antibiotic prophylaxis:
      • Meta-analysis, 3 RCTs, 482 women, antibiotics (nitrofurantoin 50mg or 100mg, TMP-SMX 400-80mg daily) versus non-antibiotics (oral lactobacillus, vaginal estrogen, or D-mannose powder):3
        • ≥1 microbiological recurrence: 43% antibiotics versus 54% non-antibiotics; NNT=9.
        • No difference in adverse events.
        • Limitations: Large variation between comparators.
      • A small RCT not included in above meta-analysis showed no benefit.4
Context
  • Recurrent UTIs defined as: ≥3 episodes in 12 months, or 2 episodes in 6 months.5,6
  • No significant difference between nitrofurantoin and other antibiotics for UTI reduction;7 however, nitrofurantoin increased adverse events (example gastrointestinal) (~1.8x).
  • Rare cases of pulmonary toxicity with nitrofurantoin [1/5000 (acute) and 1/750-7500 (chronic)].8
  • One RCT, TMP-SMX versus lactobacillus: TMP-SMX resistance increased to 80-95% during treatment but returned to baseline (20-40%) after treatment.9
    • No difference in UTI recurrence 3 months after prophylaxis was stopped.
  • One cohort reported bacterial resistance to be 16% in controls and 21% in those receiving prophylactic antibiotics at 30 days to 1-year, clinical impact unclear.10

Magdi Soliman September 4, 2022

Thanks

Gilbert Bretecher November 5, 2022

prefer use of a sulpha for prophylaxis

Gilbert Bretecher November 5, 2022

sulpha for prophylaxis is safest

Latest Tools for Practice
Derniers outils pour la pratique
program image
December 6, 2024

#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy

How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
Read Lire 0.25 credits available Crédits disponibles
program image
November 22, 2024

#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?

What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
Read Lire 0.25 credits available Crédits disponibles
program image
November 8, 2024

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Read Lire 0.25 credits available Crédits disponibles
September 4, 2022

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session
Author(s)
Auteur(s)
  • Caitlin Finley MSc MD
  • Jamie Falk BSc(Pharm) PharmD
  • Christina Korownyk MD CCFP

1. Albert X, Huertas I, Pereiro I, et al. Cochrane Database Syst Rev. 2004; 3:CD001209.

2. Rudenko N, Dorofeyev A. Drug Res. 2005; 55:420−7.

3. Ahmed H, Davies F, Francis N, et al. BMJ Open. 2017; 7:e015233.

4. McMurdo MET, Argo I, Phillips G, et al. J Antimicrob Chemother. 2009; 63:389-95.

5. Bugs and Drugs. Treatment recommendations: recurrent cystitis. Alberta Health Services. Available at: https://www.bugsanddrugs.org/6B8724C9-6CDC-480F-8263-FCF94DA89FD9. Accessed March 14, 2022.

6. DynaMed. Recurrent Cystitis in Women. EBSCO Information Services. Available at: https://www.dynamed.com/condition/recurrent-cystitis-in-women. Accessed March 14, 2022.

7. Price JR, Guran LA, Gregory WT, et al. Am J Obstet Gynecol. 2016; 548-60.

8. LeBras M, Gauthier A. RxFiles Q&A Summary. March 2017. Available from: https://www.rxfiles.ca/RxFiles/uploads/documents/Nitrofurantoin-Pulmonary-Toxicity.pdf Accessed August 29, 2022.

9. Beerepoot MA, ter Riet G, Nys S, et al. Arch Intern Med. 2012; 172:704-12.

10. Langford BJ, Brown KA, Diong C, et al. Clin Infect Dis. 2021; 73(3):e782-e791.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.